


REPLACED BY
ART 84 AMDTCLAIMS

1. A compound of formula:



5 where:

X is C=O or CR₂;

n is an integer of value 1 to 6;

Y is L(A)_m- or R¹R²CR- where L is a metal complexing agent,

A is -CR₂-, -CR=CR-, -C≡C-, -NRCO-, -CONR-, -SO₂NR-,

10 -NRSO₂-, -CR₂OCR₂-, -CR₂SCR₂-, -CR₂NRCR₂-, a C₄₋₈

cycloheteroalkylene group, a C₄₋₈ cycloalkylene group, a C₅₋₁₂ arylene

group, a C₃₋₁₂ heteroarylene group or a polyalkyleneglycol, polylactic acid
or polyglycolic acid moiety;

m is an integer of value 0 to 10;

15 where one of R¹ and R² is -NH(B)_pZ¹ and the other is
-CO(B)_qZ² where

p and q are integers of value 0 to 45, and

each B is independently chosen from Q or an amino acid
residue,

20 where Q is a cyclic peptide;

Z¹ and Z² are protecting groups;

J and each R group are independently chosen from H, C₁₋₄
alkyl, C₁₋₄ alkenyl, C₁₋₄ alkynyl, C₁₋₄ alkoxyalkyl or C₁₋₄ hydroxyalkyl;
with the provisos that:

25 (i) the total number of amino acid residues in the R¹ and R²
groups does not exceed 45;

(ii) when X is CR₂, then Y is -CRR¹R² and Z² is a metal
complexing agent;

(iii) when Y is -CRR¹R² then at least one of R¹ and R² bears at

30 least one detectable moiety.

2. The compound of claim 1 where R^1 or R^2 includes one or more peptide fragments of α_2 -antiplasmin, fibronectin, beta-casein, tetanus, amyloid, trappin and polyglutamine residues, said peptide fragment containing at least three amino acid residues.

5

3. The compound of claim 2 where the peptide fragment is from α_2 -antiplasmin.

4. The compound of claim 3 where the amino acid in the 2-
10 position from the peptide N-terminus is glutamine.

5. The compound of ~~claims 1 to 4~~ ^{Claim 1} where J is H.

6. The compound of claim 5 of formula:
15 $Y-(CR_2)_x-(CH_2)_2CONH_2$ or $Y-(CR_2)_y-(CH_2)_4NH_2$
where x is an integer of value 0 to 4, and y is an integer of value 0 to 3.

7. The compound of ~~any one of claims 1 to 6~~ ^{Claim 1} where Y is $-CRR^1R^2$.

20

8. The compound of ~~any one of claims 1 to 7~~ ^{Claim 1} where at least one of Z^1 and Z^2 is a metal complexing agent.

9. The compound of claim 8 where Z^2 is a metal complexing agent and Z^1 is not a metal complexing agent.
25

10. A metal complex of the compounds of claim 8 ~~or claim 9~~.


11. The metal complex of claim 10 where the metal is a
30 radiometal.

12. The radiometal complex of claim 11 where the radiometal is ^{99m}Tc .

13. A preparation for human administration comprising the compound of ~~any one of claims 1 to 12.~~

14. ~~A kit comprising the compound of any one of claims 1 to 9 useful in the preparation of the metal complexes of any one of claims 10 to 12.~~

15. Use for the diagnosis of sites of thrombosis or embolism of a compound of formula:



where:

- 15 X is C=O or CR₂;
 n is an integer of value 1 to 6;
 Y is L(A)_m- or R¹R²CR- where L is a metal complexing agent,
 A is -CR₂-, -CR=CR-, -C≡C-, -NRCO-, -CONR-, -SO₂NR-,
 -NRSO₂-, -CR₂OCR₂-, -CR₂SCR₂-, -CR₂NRCR₂-; a C₄₋₈
 20 cycloheteroalkylene group, a C₄₋₈ cycloalkylene group, a C₅₋₁₂ arylene
 group, a C₃₋₁₂ heteroarylene group or a polyalkyleneglycol, polylactic acid
 or polyglycolic acid moiety;
 m is an integer of value 0 to 10;
 where one of R¹ and R² is -NH(B)_pZ¹ and the other is
 25 -CO(B)_qZ² where
 p and q are integers of value 0 to 45, and
 each B is independently chosen from Q or an amino acid
 residue,
 where Q is a cyclic peptide;
 30 Z¹ and Z² are protecting groups;

- 37 -

J and each R group are independently chosen from H, C₁₋₄ alkyl, C₁₋₄ alkenyl, C₁₋₄ alkynyl, C₁₋₄ alkoxyalkyl or C₁₋₄ hydroxyalkyl; with the provisos that:

- (i) the total number of amino acid residues in the R¹ and R² groups does not exceed 45;
- (ii) when X is CR₂, then Y is -CRR¹R²;
- (iii) when Y is -CRR¹R² then at least one of R¹ and R² bears at least one detectable moiety.
- 10 16. Use for the diagnosis of sites of thrombosis or embolism of a radiometal complex of the compound defined in claim 13, wherein at least one of Z¹ and Z² is a metal complexing agent.
- 15 17. A peptide fragment of α_2 -antiplasmin, fibronectin, beta-casein, tetanus, amyloid, trappin or polyglutamine, said peptide fragment containing 3 – 45 amino acid residues and carrying a terminal metal complexing agent.
- 20 18. The peptide fragment of claim 17, wherein the metal complexing agent is at the carboxy terminus.

19. A metal complex of the peptide fragment of claim 17 ~~or~~
~~claim 18.~~